首页 > 最新文献

Pharmaceutical patent analyst最新文献

英文 中文
Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market. 药品专利及其对药品获取的影响:以撒哈拉以南非洲市场为重点。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-01 Epub Date: 2022-09-30 DOI: 10.4155/ppa-2022-0044
Shemaiah O Okeniyi, Melody Okereke
{"title":"Pharmaceutical patents and their impact on access to medicines: a focus on the sub-Saharan Africa market.","authors":"Shemaiah O Okeniyi, Melody Okereke","doi":"10.4155/ppa-2022-0044","DOIUrl":"https://doi.org/10.4155/ppa-2022-0044","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40385077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ever-expanding landscape: Alzheimer's - new targets and new patents. 不断扩张的版图:阿尔茨海默病——新的目标和新的专利。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-01 Epub Date: 2022-09-02 DOI: 10.4155/ppa-2022-0031
Ayodeji O Egunlusi, Jacques Joubert
{"title":"Ever-expanding landscape: Alzheimer's - new targets and new patents.","authors":"Ayodeji O Egunlusi, Jacques Joubert","doi":"10.4155/ppa-2022-0031","DOIUrl":"https://doi.org/10.4155/ppa-2022-0031","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40344699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer. 高度稳定、无毒、功能化的纳米乳,用于癌症的早期诊断和改善。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-01 Epub Date: 2022-10-06 DOI: 10.4155/ppa-2021-0029
Ramesh Joga, Christy J Pulini-Kunnel, Chetan D Sabanis, Simran, Sandeep Kumar, Neeraj Kumar

Aim: To overcome the limitations associated with conventional formulations for cancer treatment by the effective utilization of nanoemulsion with therapy and diagnosis through the single unit. Patent: US20210275687 describes the usage of functionalized various oil-in-water nanoemulsions as pharmacological vehicles with theranostic potential in cancer treatment. Materials & methods: Vitamin E, oleic acid, sphingomyelin, ligands for functionalization, contrast agents and therapeutic biomolecules. Results: The toxicity studies conducted on healthy mice did not show any apparent toxicity issues. The stability studies conducted at 40 °C and 75% relative humidity, which is mandatory for regulatory approval, indicated the adequate physical stability of the formulation. Conclusion: The studies exhibited the promising theranostic potential of the developed nanoemulsion for the effective management and diagnosis of cancer and metastatic diseases.

目的:有效利用纳米乳,通过单一单元进行治疗和诊断,以克服常规配方治疗癌症的局限性。专利号:US20210275687描述了功能化的各种水包油纳米乳液作为具有癌症治疗潜力的药理学载体的用途。材料与方法:维生素E、油酸、鞘磷脂、功能化配体、造影剂和治疗性生物分子。结果:对健康小鼠进行的毒性研究未发现任何明显的毒性问题。稳定性研究在40°C和75%相对湿度下进行,这是监管部门批准的强制性要求,表明该配方具有足够的物理稳定性。结论:研究表明,所研制的纳米乳在有效治疗和诊断癌症和转移性疾病方面具有良好的治疗潜力。
{"title":"Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer.","authors":"Ramesh Joga,&nbsp;Christy J Pulini-Kunnel,&nbsp;Chetan D Sabanis,&nbsp;Simran,&nbsp;Sandeep Kumar,&nbsp;Neeraj Kumar","doi":"10.4155/ppa-2021-0029","DOIUrl":"https://doi.org/10.4155/ppa-2021-0029","url":null,"abstract":"<p><p><b>Aim:</b> To overcome the limitations associated with conventional formulations for cancer treatment by the effective utilization of nanoemulsion with therapy and diagnosis through the single unit. <b>Patent:</b> US20210275687 describes the usage of functionalized various oil-in-water nanoemulsions as pharmacological vehicles with theranostic potential in cancer treatment. <b>Materials & methods:</b> Vitamin E, oleic acid, sphingomyelin, ligands for functionalization, contrast agents and therapeutic biomolecules. <b>Results:</b> The toxicity studies conducted on healthy mice did not show any apparent toxicity issues. The stability studies conducted at 40 °C and 75% relative humidity, which is mandatory for regulatory approval, indicated the adequate physical stability of the formulation. <b>Conclusion:</b> The studies exhibited the promising theranostic potential of the developed nanoemulsion for the effective management and diagnosis of cancer and metastatic diseases.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33490176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Oxaliplatin-flavone pharmaceutical co-crystal-CN111205332A: patent spotlight. 奥沙利铂-黄酮类药物共晶cn111205332a:专利聚光灯。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-09-01 Epub Date: 2022-09-02 DOI: 10.4155/ppa-2022-0011
Ritu Rathi, Renu Kushwaha, Ayushi Goyal, Inderbir Singh

Co-crystallization is a technique for modifying physicochemical properties of pharmaceutical ingredients with an aim to enhance the therapeutic efficacy and subsequent reduction in toxicity. The patent describes the development of oxaliplatin co-crystals using flavonoids (baicalein and naringenin) via solvent volatilization technique with an objective to improve solubility and stability in GI tract and reduced side/toxic effects. The co-crystals were characterized via differential scanning calorimetry, thermogravimetric analysis, x-ray diffraction analysis. The co-crystals exhibited slow drug release, delayed hydrolysis, low cytotoxicity and enhanced therapeutic activity on human gastric adenocarcinoma cells. However, suitable solvent for co-crystal production, large scale production and regulatory challenges for continuous manufacturing of co-crystals must be addressed.

共结晶是一种通过改变药物成分的物理化学性质来提高治疗效果和降低毒性的技术。该专利描述了利用黄酮类化合物(黄芩素和柚皮素)通过溶剂挥发技术开发奥沙利铂共晶,目的是提高其在胃肠道中的溶解度和稳定性,减少副作用/毒性作用。通过差示扫描量热法、热重分析、x射线衍射分析对共晶进行了表征。该共晶具有药物释放缓慢、水解延迟、细胞毒性低、对人胃腺癌细胞的治疗活性增强等特点。然而,合适的共晶生产溶剂、大规模生产和连续生产共晶的监管挑战必须得到解决。
{"title":"Oxaliplatin-flavone pharmaceutical co-crystal-CN111205332A: patent spotlight.","authors":"Ritu Rathi,&nbsp;Renu Kushwaha,&nbsp;Ayushi Goyal,&nbsp;Inderbir Singh","doi":"10.4155/ppa-2022-0011","DOIUrl":"https://doi.org/10.4155/ppa-2022-0011","url":null,"abstract":"<p><p>Co-crystallization is a technique for modifying physicochemical properties of pharmaceutical ingredients with an aim to enhance the therapeutic efficacy and subsequent reduction in toxicity. The patent describes the development of oxaliplatin co-crystals using flavonoids (baicalein and naringenin) via solvent volatilization technique with an objective to improve solubility and stability in GI tract and reduced side/toxic effects. The co-crystals were characterized via differential scanning calorimetry, thermogravimetric analysis, x-ray diffraction analysis. The co-crystals exhibited slow drug release, delayed hydrolysis, low cytotoxicity and enhanced therapeutic activity on human gastric adenocarcinoma cells. However, suitable solvent for co-crystal production, large scale production and regulatory challenges for continuous manufacturing of co-crystals must be addressed.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40341256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights February-March 2022. 专利亮点:2022年2月至3月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0013
Hermann Am Mucke

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

与制药和医学研究与开发相关的专利文献中值得注意的最新发展概况。
{"title":"Patent highlights February-March 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0013","DOIUrl":"https://doi.org/10.4155/ppa-2022-0013","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40634287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Six drugs facing key patent expirations and potential generic entry from May to June 2022. 2022年5月至6月,6种药物面临关键专利到期和潜在仿制药上市。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-07-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0018
Yali Friedman

A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.

预测仿制药进入的一个挑战是阐明哪些专利和监管保护限制仿制药进入。这里展示的是一组估计的6种药物独占性丧失日期,从2022年5月到6月。这些估计的药物专利到期日期和仿制药进入机会日期是通过对已知专利和美国药品监管保护的分析计算得出的[1]。通过利用这些估算和跟踪其他专利局的专利家族成员,这种方法可以扩展到美国以外的司法管辖区。
{"title":"Six drugs facing key patent expirations and potential generic entry from May to June 2022.","authors":"Yali Friedman","doi":"10.4155/ppa-2022-0018","DOIUrl":"https://doi.org/10.4155/ppa-2022-0018","url":null,"abstract":"<p><p>A challenge in anticipating generic entry is elucidating which patents and regulatory protections constrain generic entry. Presented here is a set of estimated loss of exclusivity dates for six drugs, from May through June 2022. These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents and US regulatory protections covering drugs [1]. This methodology can be extended to ex-US jurisdictions by leveraging these estimates and tracking patent family members in other patent offices.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40610023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent update on drug patent linkage system in China. 中国药品专利联动制度最新进展。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-06-14 DOI: 10.4155/ppa-2022-0012
Weiwei Han
{"title":"Recent update on drug patent linkage system in China.","authors":"Weiwei Han","doi":"10.4155/ppa-2022-0012","DOIUrl":"https://doi.org/10.4155/ppa-2022-0012","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42932865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry. 瑞德西韦:新冠肺炎治疗的专利趋势、临床证据、药理学和化学综述。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-05-31 DOI: 10.4155/ppa-2021-0023
Sandro G Viveiros Rosa, W. C. Santos
By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.
截至2021年12月,新冠肺炎在全球造成约610万人死亡。一些疫苗已经获得批准,但仍需要对新冠肺炎进行非预防性治疗。Remdesivir是一种抗病毒药物,在几个国家被批准紧急用于治疗新冠肺炎,但首批临床试验之一对降低死亡率没有结论,尽管该药物显示住院患者的恢复时间缩短。因此,本研究重新审视了使用瑞德西韦治疗新冠肺炎的临床证据、专利状况、药理学和化学。我们在Cortellis数据库中发现了184个专利家族,关于临床证据,我们检索了14篇涉及瑞德西韦治疗新冠肺炎的系统综述和荟萃分析,讨论了不良事件的减少、住院天数、死亡率和机械通气期。
{"title":"Remdesivir: an overview of patenting trends, clinical evidence on COVID-19 treatment, pharmacology and chemistry.","authors":"Sandro G Viveiros Rosa, W. C. Santos","doi":"10.4155/ppa-2021-0023","DOIUrl":"https://doi.org/10.4155/ppa-2021-0023","url":null,"abstract":"By December 2021, the COVID-19 caused approximately 6.1 million deaths around the world. Several vaccines have been approved, but there is still a need for non-prophylactic treatments for COVID-19. Remdesivir is an antiviral drug approved for emergency use against COVID-19 in several countries, but one of the first clinical trials was inconclusive about the mortality reduction, although the drug showed a reduction in the recovery time of hospitalized patients. Thus, the present investigation revisits the clinical evidence of using remdesivir for COVID-19 treatment, patent status, pharmacology and chemistry. We found 184 families of patents in the Cortellis database, and concerning the clinical evidence, we retrieved 14 systematic reviews with meta-analysis involving remdesivir as a treatment for COVID-19, discussing the reduction of adverse events, hospitalization days, mortality rate and the mechanical ventilation period.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44349785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Patent highlights October-November 2021. 专利亮点2021年10月至11月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-05-31 DOI: 10.4155/ppa-2022-0003
H. Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
与药物和医学研发相关的专利文献中值得注意的最新进展的快照。
{"title":"Patent highlights October-November 2021.","authors":"H. Mucke","doi":"10.4155/ppa-2022-0003","DOIUrl":"https://doi.org/10.4155/ppa-2022-0003","url":null,"abstract":"A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45317231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights December 2021-January 2022. 专利亮点2021年12月至2022年1月。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2022-05-01 Epub Date: 2022-07-21 DOI: 10.4155/ppa-2022-0006
Hermann Am Mucke

A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.

与制药和医学研究与开发相关的专利文献中值得注意的最新发展概况。
{"title":"Patent highlights December 2021-January 2022.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2022-0006","DOIUrl":"https://doi.org/10.4155/ppa-2022-0006","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40612852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pharmaceutical patent analyst
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1